Background The rheumatoid arthritis is one of the most severe and widespread systemic inflammatory autoimmune diseases. The biomarkers play an important role in early diagnostics, activity evaluation, severity of disease course, disease prognosis and effectiveness of applied therapy. Traditional inflammatory biomarkers such as ESR (erythrocyte sedimentation rate) and CRP (c-reactive protein) can be in the normal range in approximately 40% of RA patients. MBDA has been proposed as an objective measure of disease activity for patients with RA. MBDA is a cumulative score based on the serum concentrations of 12 serum proteins (biomarkers); the score has been validated for use in RA. MBDA can provide a baseline assessment of RA disease activity and track it over time. But Interpretation of individual biomarker results has not been validated.
Objectives To compare the MBDA (VECTRA-DA) scores with traditional serologic markers of inflammation (ESR, CRP), as well as the relative contribution of the individual cytokines comprising the MBDA, for the assessment of RA activity in a real life clinical practice setting.
Methods A retrospective chart review study was conducted in an urban teaching hospital and 150 patients with RA were identified, fulfilling the 2010 ACR diagnostic criteria. The study was approved by the ethics committee, and simultaneous blood draws were performed for Vectra-DA, ESR and CRP during routine clinic visits over a period of one year. We compared the VECTRA test results in Rheumatoid Arthritis patients with ESR and CRP (Table 1) and analyzed the contribution of the individual components of the MBDA toward its composite score.
Results see Table 1.
Conclusions The novel MBDA test VECTRA-DA provides additional information, beyond the traditional serologic markers of inflammation ESR and CRP, toward the assessment of RA disease activity. VCAM, TNF-RI and IL-6 levels appear to have a major influence on the composite MBDA score that is associated with disease activity.
Disclosure of Interest S. Chittalae: None declared, O. Shuaib: None declared, H. Hakeem: None declared, S. Kadavath: None declared, M. Briggs: None declared, P. Efthimiou Consultant for: crescendo bioscience